Abstract
Objective We investigated the association between new-onset atrial fibrillation (AF) and risk of stroke and myocardial infarction (MI) in patients with abdominal aortic aneurysmal (AAA) disease.
Methods Observational crossover study using Danish nationwide data, including patients with AAA and incident AF between 1997 and 2018. We estimated the 1-year risk of stroke and MI and the within-individual odds ratios (ORs) of ischemic events before and after an AF diagnosis, stratified by year of AF diagnosis (1997–2010 and 2011–2018), and supplemented with analyses on changes in use of antithrombotic therapy.
Results A total of 3,035 AAA patients were included: 1,040 diagnosed during 1997 to 2010, and 1,995 during 2011 to 2018 (22.2% females, median age 78 years; median CHA2DS2-VASc score 4; interquartile range: 3–5). One-year risk of ischemic events after AF was 5.9% (confidence interval [CI] 95%: 4.6–7.5%) and 4.5% (CI 95%: 3.7–5.5%) for stroke and 5.4% (CI 95%: 4.2–6.9%) and 4.0% (CI 95%: 3.2–4.9%) for MI during 1997 to 2010 and 2011 to 2018, respectively. The OR of ischemic stroke before and after incident AF was 2.8 (CI 95%: 1.6–5.2) during 1997 to 2010; and 2.4 (CI 95%: 1.5 to 3.9) during 2011 to 2018, and 3.5 (CI 95%: 1.7–7.5) and 1.5 (CI 95%: 0.9–2.4) for MI. One-year proportion of prescription claims for oral anticoagulants after AF changed from 66.1% in 1997 to 2010 to 82.6% in 2011 to 2018, while antiplatelet prescription claims changed from 80.8 to 60.9%.
Conclusion Cardiovascular prognosis has improved in patients with prevalent AAA disease and new-onset AF in concordance with optimization of antithrombotic therapy over time. A diagnosis of AF conferred residual risk of stroke and MI.
Methods Observational crossover study using Danish nationwide data, including patients with AAA and incident AF between 1997 and 2018. We estimated the 1-year risk of stroke and MI and the within-individual odds ratios (ORs) of ischemic events before and after an AF diagnosis, stratified by year of AF diagnosis (1997–2010 and 2011–2018), and supplemented with analyses on changes in use of antithrombotic therapy.
Results A total of 3,035 AAA patients were included: 1,040 diagnosed during 1997 to 2010, and 1,995 during 2011 to 2018 (22.2% females, median age 78 years; median CHA2DS2-VASc score 4; interquartile range: 3–5). One-year risk of ischemic events after AF was 5.9% (confidence interval [CI] 95%: 4.6–7.5%) and 4.5% (CI 95%: 3.7–5.5%) for stroke and 5.4% (CI 95%: 4.2–6.9%) and 4.0% (CI 95%: 3.2–4.9%) for MI during 1997 to 2010 and 2011 to 2018, respectively. The OR of ischemic stroke before and after incident AF was 2.8 (CI 95%: 1.6–5.2) during 1997 to 2010; and 2.4 (CI 95%: 1.5 to 3.9) during 2011 to 2018, and 3.5 (CI 95%: 1.7–7.5) and 1.5 (CI 95%: 0.9–2.4) for MI. One-year proportion of prescription claims for oral anticoagulants after AF changed from 66.1% in 1997 to 2010 to 82.6% in 2011 to 2018, while antiplatelet prescription claims changed from 80.8 to 60.9%.
Conclusion Cardiovascular prognosis has improved in patients with prevalent AAA disease and new-onset AF in concordance with optimization of antithrombotic therapy over time. A diagnosis of AF conferred residual risk of stroke and MI.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Thrombosis and Haemostasis |
| Vol/bind | 123 |
| Udgave nummer | 5 |
| Sider (fra-til) | 555-564 |
| Antal sider | 10 |
| ISSN | 0340-6245 |
| DOI | |
| Status | Udgivet - 2023 |
Bibliografisk note
Funding Information:M. Søgaard has received consulting fees from Bayer. N. Eldrup has served as an investigator for Bayer, and has received fees for speaking engagement from Bayer, Amgen, and AstraZeneca. T.B. Larsen has served as an investigator for Janssen Scientific Affairs, LLC, Larsen has also participated in speaker panels for Bayer, Bristol-Myers Squibb/Pfizer and Roche Diagnostics; Larsen has also received honoraria for consulting activities from Bayer AG, Bristol-Myers Squibb and Pfizer. T.B. Larsen’s institution has received unrestricted funds for investigator-initiated research activities from Bayer, Pfizer, and Daiichi Sankyo. P. B. Nielsen has received fees for speaking engagements from Boehringer Ingelheim and BMS/Pfizer; fees for consulting from Bayer and Daiichi-Sankyo; and grant support from BMS/Pfizer and Daiichi-Sankyo Europe. All other authors declare no conflicts of interest.
Publisher Copyright:
© 2022 Georg Thieme Verlag. All rights reserved.